A Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Study Name:
A Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Targeted Disease(s):
Lung Cancer

Purpose of Study:

To evaluate the safety and tolerability of ADXS-503, administered as monotherapy in Part A and in combination with pembrolizumab in Part B, and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD). As well, to characterize the preliminary anti-tumor activity of ADXS-503, administered in combination with pembrolizumab in Part C, per RECIST v1.1.

Study Dates:
February 1, 2019 - March 1, 2023

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Funding Source:
Advaxis

ClinicalTrails.gov Identifier:
NCT03847519

Register for Trial
Freedom From Smoking Clinic
, | May 02, 2022
Freedom From Smoking Clinic
Virginia Beach, VA | May 10, 2022